Current Report Filing (8-k)
July 15 2019 - 4:50PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 15,
2019
KRAIG BIOCRAFT LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Wyoming
|
|
|
|
83-0458707
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2723
South State St. Suite 150
Ann Arbor, Michigan 48104
(Address of principal executive offices, including Zip
Code)
(734) 619-8066
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
None
|
|
-
|
|
-
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (?230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
On July 14,
2019, Kraig
Biocraft Laboratories, Inc. (the “Company”) issued a
letter to its shareholders relating to its annual shareholder
meeting to be held on July 24, 2019. This letter was sent out the
the Company's opt in email distribution list and posted to the
Company's website. A copy of that letter to shareholders is
filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
Exhibit
No.
|
Description
|
99.1
|
Letter
to shareholder dated July 14
th
, 2019
|
|
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
July [ ], 2019
|
KRAIG BIOCRAFT LABORATORIES, INC.
|
|
|
|
|
By:
|
/s/ Kim
Thompson
|
|
|
Kim
Thompson
|
|
|
Chief
Executive Officer, Chief Financial Officer and
Director
|
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Sep 2023 to Sep 2024